From active-ingredient characterisation to industrial transfer: studies, launches, technologies and formulation questions for food supplement developers.
The protocol contrasts more than 1,000 mg/kg with no more than 100 mg/kg total polyphenols alongside metabolic, anthropometric and wellbeing outcomes.
Read the analysis →Use moved from 1.8% to 6.96% among adults and from 0.63% to 5.58% among under‑20s, while fibre intake changed little.
Read the analysis →Only the high dose of the seven-strain consortium increased serum folate and reduced homocysteine, with dose-dependent transient intestinal persistence.
Read the analysis →The probiotic group showed lower plasma pTau181 and selective advantages in visuospatial construction and memory, with no between-group difference in MMSE, verbal memory or executive function.
Read the analysis →Its exhibition presence confirms an emerging microbiome + muscle-health category alongside protein, creatine and healthy ageing.
Read the analysis →Authors report improvements in emotional well-being, gastrointestinal symptoms and sleep quality alongside microbiota and inflammatory-marker changes.
Read the analysis →OGTT and almost all continuous-monitoring indices remained comparable between groups; some favourable baseline changes did not establish a fortification effect.
Read the analysis →Nestlé’s strategy confirms that GLP-1 companion nutrition is becoming a recognisable industrial category rather than a communication trend alone.
Read the analysis →Moving from voluntary notification to a requirement could increase transparency and oversight while also affecting timelines, resources and US market-entry planning.
Read the analysis →Agents executed code and experiments but struggled with research design, strategic pivots, resource awareness and the threshold for publishable work.
Read the analysis →Compared with placebo, the study reported lower fasting and postprandial glucose and higher GLP-1, alongside favourable lipid changes.
Read the analysis →Launch communication frames the delivery technology through encapsulation efficiency, stability and performance criteria.
Read the analysis →Separation technology, mass spectrometry, fermentation, ultrasound and high pressure broaden the development space, but much of the evidence remains preclinical.
Read the analysis →EFSA considers the Novel Food safe under the proposed uses and levels in foods, infant formula, supplements and foods for special medical purposes.
Read the analysis →Urolithins, equol and other metabolites emerge as potential functional biomarkers for research and trial stratification, not yet routine prescribing tools.
Read the analysis →Results differ with the ratio of extract to matrix: some endpoints improve, others remain unchanged or move in an unfavourable direction.
Read the analysis →Favourable differences appeared in selected cognitive tests, but the whole profile did not improve uniformly and the sample remains small.
Read the analysis →Four weeks of supplementation attenuated gastrointestinal symptoms, permeability and inflammation versus placebo in a highly specific sports context.
Read the analysis →The system structures 35 strain-compound associations and demonstrates a concrete role for language models in early discovery.
Read the analysis →The collection shows why mechanisms, composition, preclinical models and clinical work must converge before a natural signal becomes a robust product rationale.
Read the analysis →The trend does not replace individual-ingredient rationale; it adds the need to measure absorption, interactions, adherence and outcomes for the marketed formula.
Read the analysis →The opinion defines the evaluated form, population and use level, providing a concrete regulatory reference for new choline-source development.
Read the analysis →The producer strain could not be conclusively assigned to a species, preventing completion of the Novel Food safety assessment.
Read the analysis →Inclusion of a plant directs documentary research but does not by itself establish that every extract, dose or product is hazardous.
Read the analysis →The workflow produced a structured dataset of 35 strain-compound associations, illustrating how AI can compress early bibliographic scouting.
Read the analysis →The work covers new forms, metabolites and molecules with vitamin activity intended for supplements, fortified foods and specific population groups.
Read the analysis →Priorities include Huperzia serrata, guggul, Coleus forskohlii, ginseng, black radish, emodin, chrysophanol and selected Bifidobacterium strains.
Read the analysis →XAI can show which variables drive an output, making it easier to compare a model with scientific plausibility, literature and experimental verification.
Read the analysis →Commercial value depends on continuity between the studied strain and the strain that is actually manufactured, stabilised, dosed and communicated.
Read the analysis →Finished-formula validation needs a sequence: identity and stability, exposure, nutritional-status change, functional outcomes and comparison with simpler alternatives.
Read the analysis →The conceptual model moves from predicting the properties of a recipe to generating combinations compatible with technical constraints and multiple objectives.
Read the analysis →New positioning treats hair as an outcome of interconnected systems and segments consumers by life stage, lifestyle and biological need.
Read the analysis →The caffeine-free botanical complex is positioned for energy, focus and mood applications, with dsm-firmenich supporting clinical, regulatory and commercial development.
Read the analysis →In 16 healthy adults, one AG1 dose increased plasma exposure for most measured nutrients compared with placebo.
Read the analysis →The trial reported fewer episodes and a lower overall burden, particularly among recurrent cases, but no significant difference in time to first infection.
Read the analysis →The project combines nutrivigilance, reports and botanical screening to identify priorities for further investigation, not an automatic list of prohibited ingredients.
Read the analysis →Six ingredients or ingredient groups and three botanical substances are identified as signals requiring further investigation, not as risks that have already been conclusively established.
Read the analysis →Topic pages connect current reporting with the permanent archive.
Receive the editorial selection or request a free introductory conversation on using AI tools and automation in nutraceutical work.
GMA